{
    "clinical_study": {
        "@rank": "154844", 
        "brief_summary": {
            "textblock": "Patient with advanced liver cancer (cancer that has spread to other parts of the body)\n      continues to receive the study drug (G-202) even though patient no longer meets the criteria\n      to be a part of the main treatment study.  Patient's cancer responded well to receiving\n      G-202 in the main study and will receive G-202 at the same dose given in the main study."
        }, 
        "brief_title": "Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma", 
        "condition": "Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History of hepatocellular carcinoma\n\n          -  Participation in prior research study where G-202 was administered\n\n          -  Tolerance of G-202 treatment\n\n          -  Demonstration of stable disease\n\n        Exclusion Criteria:\n\n          -  Disease progression\n\n          -  Occurrence of unacceptable toxicity"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "id_info": {
            "nct_id": "NCT02082691", 
            "org_study_id": "CTRC 13-0040", 
            "secondary_id": "HSC20130391T [UTHSCSA IRB]"
        }, 
        "intervention": {
            "description": "Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202.  This cycle will be repeated every 28 days.  Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.", 
            "intervention_name": "G-202", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "G-202", 
            "Hepatocellular"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "official_title": "Single Patient IND: Continued Administration of G-202 to a Patient With Advanced Hepatocellular Carcinoma Previously Treated With G-202 and Receiving Clinical Benefit", 
        "overall_official": {
            "affiliation": "University of Texas Health Science Center San Antonio", 
            "last_name": "Devalingam Mahalingam, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "No longer available", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ]
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02082691"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of Texas Health Science Center at San Antonio", 
            "investigator_full_name": "Devalingam Mahalingam", 
            "investigator_title": "Prinicipal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "The University of Texas Health Science Center at San Antonio", 
        "sponsors": {
            "collaborator": {
                "agency": "GenSpera, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Devalingam Mahalingam", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "March 2014"
    }
}